1745-P: Long-Term Safety and Efficacy of Once-Weekly Dosage of 2.4 mg Semaglutide for Weight Loss in Patients with and without Diabetes—An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials

IF 7.5 1区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes Pub Date : 2025-06-13 DOI:10.2337/db25-1745-p

MIAN MUHAMMAD SALMAN ASLAM, WANIA U. REHMAN, QURAT UL AIN M. MUHAMMAD, MUHAMMAD TALHA SHAUKAT, MUHAMMAD HASSNAIN NASRULLAH, MUHAMMAD HASSAN, FATIMA SAEED, MUHAMMAD A. TARIQ

{"title":"1745-P: Long-Term Safety and Efficacy of Once-Weekly Dosage of 2.4 mg Semaglutide for Weight Loss in Patients with and without Diabetes—An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials","authors":"MIAN MUHAMMAD SALMAN ASLAM, WANIA U. REHMAN, QURAT UL AIN M. MUHAMMAD, MUHAMMAD TALHA SHAUKAT, MUHAMMAD HASSNAIN NASRULLAH, MUHAMMAD HASSAN, FATIMA SAEED, MUHAMMAD A. TARIQ","doi":"10.2337/db25-1745-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: Obesity is a multifaceted health crisis necessitating a nuanced understanding to direct evidence-based therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP1RAs) such as semaglutide have shown encouraging yet contradictory outcomes. This study aims to evaluate the long-term efficacy and safety of once-weekly 2.4 mg semaglutide for weight loss in patients with and without diabetes. Methods: A systematic search was conducted in MEDLINE (via PubMed), Cochrane Library, Google Scholar, and ClinicalTrials.gov up to December 31, 2024, for relevant randomized controlled trials (RCTs) comparing semaglutide versus placebo. The protocol was registered on PROSPERO (ID: CRD42024532538). Meta-analysis was performed using R statistical software to calculate mean differences (MD), risk ratios (RR), and corresponding 95% confidence intervals (CI). Results: Twelve RCTs with 23,600 participants (semaglutide: 12,492; placebo: 11,108) were included. Semaglutide significantly reduced body weight compared to placebo, with a mean percentage reduction of -7.91% and an absolute reduction of -10.40 kg (p &lt; 0.01). Higher proportions of patients in the semaglutide group achieved weight loss thresholds of ≥10%, ≥15%, and ≥20% (p &lt; 0.01). Waist circumference, fasting plasma glucose, and lipid profiles improved (p &lt; 0.01). Adverse events, primarily gastrointestinal, were more common with semaglutide (RR = 1.56; p &lt; 0.01), contributing to higher discontinuation rates (RR = 4.67; p &lt; 0.01). Conclusion: Semaglutide demonstrates robust efficacy in achieving significant weight loss and improving metabolic parameters in patients with and without diabetes. However, its tolerability remains a challenge, warranting further research to optimize safety. Disclosure M. Aslam: None. W.U. Rehman: None. Q.M. Muhammad: None. M. Shaukat: None. M. Nasrullah: None. M. Hassan: None. F. Saeed: None. M.A. Tariq: None.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"49 1","pages":""},"PeriodicalIF":7.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db25-1745-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objective: Obesity is a multifaceted health crisis necessitating a nuanced understanding to direct evidence-based therapeutic strategies. Glucagon-like peptide-1 receptor agonists (GLP1RAs) such as semaglutide have shown encouraging yet contradictory outcomes. This study aims to evaluate the long-term efficacy and safety of once-weekly 2.4 mg semaglutide for weight loss in patients with and without diabetes. Methods: A systematic search was conducted in MEDLINE (via PubMed), Cochrane Library, Google Scholar, and ClinicalTrials.gov up to December 31, 2024, for relevant randomized controlled trials (RCTs) comparing semaglutide versus placebo. The protocol was registered on PROSPERO (ID: CRD42024532538). Meta-analysis was performed using R statistical software to calculate mean differences (MD), risk ratios (RR), and corresponding 95% confidence intervals (CI). Results: Twelve RCTs with 23,600 participants (semaglutide: 12,492; placebo: 11,108) were included. Semaglutide significantly reduced body weight compared to placebo, with a mean percentage reduction of -7.91% and an absolute reduction of -10.40 kg (p < 0.01). Higher proportions of patients in the semaglutide group achieved weight loss thresholds of ≥10%, ≥15%, and ≥20% (p < 0.01). Waist circumference, fasting plasma glucose, and lipid profiles improved (p < 0.01). Adverse events, primarily gastrointestinal, were more common with semaglutide (RR = 1.56; p < 0.01), contributing to higher discontinuation rates (RR = 4.67; p < 0.01). Conclusion: Semaglutide demonstrates robust efficacy in achieving significant weight loss and improving metabolic parameters in patients with and without diabetes. However, its tolerability remains a challenge, warranting further research to optimize safety. Disclosure M. Aslam: None. W.U. Rehman: None. Q.M. Muhammad: None. M. Shaukat: None. M. Nasrullah: None. M. Hassan: None. F. Saeed: None. M.A. Tariq: None.

查看原文本刊更多论文

1745-P：每周一次2.4 mg西马鲁肽用于糖尿病和非糖尿病患者减肥的长期安全性和有效性——随机对照试验的最新系统评价和荟萃分析

简介和目的：肥胖是一种多方面的健康危机，需要细致入微的理解来指导循证治疗策略。胰高血糖素样肽-1受体激动剂（GLP1RAs）如semaglutide已显示出令人鼓舞但矛盾的结果。本研究旨在评估每周一次2.4 mg西马鲁肽对糖尿病和非糖尿病患者减肥的长期疗效和安全性。方法：系统检索截至2024年12月31日的MEDLINE（通过PubMed）、Cochrane Library、b谷歌Scholar和ClinicalTrials.gov，以比较semaglutide和安慰剂的相关随机对照试验（rct）。协议在PROSPERO上注册（ID: CRD42024532538）。采用R统计软件进行meta分析，计算平均差异（MD）、风险比（RR）和相应的95%置信区间（CI）。结果：12项随机对照试验共有23,600名受试者(西马鲁肽：12,492名；安慰剂组：11,108例)。与安慰剂相比，Semaglutide显著降低体重，平均百分比减少-7.91%，绝对减少-10.40 kg (p <；0.01)。西马鲁肽组患者达到≥10%、≥15%和≥20%的减重阈值的比例较高(p <；0.01)。腰围、空腹血糖和血脂改善(p <；0.01)。以胃肠道为主的不良事件在西马鲁肽组更为常见(RR = 1.56；p, lt;0.01)，导致更高的停药率(RR = 4.67；p, lt;0.01)。结论：在糖尿病患者和非糖尿病患者中，Semaglutide在实现显著的体重减轻和改善代谢参数方面表现出强大的疗效。然而，其耐受性仍然是一个挑战，需要进一步研究以优化安全性。阿斯拉姆：没有。拉赫曼：没有。穆罕默德：没有。肖卡：没有。纳斯鲁拉：没有。哈桑：没有。F.赛义德：没有。塔里克：没有。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.